Podcast: Advancing the Tech of Diabetes Decision-Making

Discussing the role of scientific advances in battling a growing health problem during a pandemic.

Diabetes Care | Dec. 11, 2020
 

Available in latest versions of Chrome, Safari, Firefox and I.E. 11.12+

 

Podcast Health Tech Listen, download and subscribe to our podcast channel:
iTunes     Spotify     Spotify

The science of medicine has always been the science of decision-making. From medieval barbers trying to optimize the bloodletting required to “cure” their patients to early surgeons determining initial incision sites through to today, healthcare providers have always focused on obtaining the best available data to inform their patients’ options.

In the latest episode of our podcast series, “Health Tech on the Horizon: Diabetes,” host Mike Rugnetta talks with John Nosta, technology theorist and founder of the digital health think tank, Nosta Lab, and Laura Brandner, Director of Real World Evidence Programs, Abbott Diabetes Care, about the importance of scientific information and subsequent medical decisions.

A particularly important data point concerns the prevalence of diabetes which has risen steadily from 108 million to more than 420 million globally from 1980-2014.

The coronavirus pandemic has also brought on a new level of risk for people with diabetes. According to the U.S. Centers for Disease Control, more than 50% of people diagnosed with both COVID-19 and diabetes have been hospitalized, a rate far higher than with other people carrying the virus.

Power of Evolution

In addition to the implications of those statistics, the podcast panel also discusses the scientific evolution of continuous glucose monitoring (CGM) and its impact on living with diabetes. While fingertip testing provides a broad picture of ongoing glucose management, monitors like the FreeStyle Libre system can provide ongoing information when it is needed most.

Enhanced monitoring data, integrated with other wearable technology, may eventually lead to more individualized care that constantly adjusts for each person.

As this fascinating panel discusses, the importance of enhanced data in improving medical decision-making and evolving technology may take much of the guesswork out of people's daily lives.

IMPORTANT SAFETY INFORMATION

FREESTYLE LIBRE 14 DAY SYSTEM

FreeStyle Libre 14 day Flash Glucose Monitoring systems are continuous glucose monitoring (CGM) devices indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. The systems are intended for single patient use and require a prescription.

CONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.

WARNINGS/LIMITATIONS: Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The system does not have alarms unless the sensor is scanned, and the system contains small parts that may be dangerous if swallowed. The system is not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. When using FreeStyle LibreLink app, access to a blood glucose monitoring system is required as the app does not provide one. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit www.freestylelibre.us for detailed indications for use and safety information.

FreeStyle Libre 2 system:

The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.*

WARNINGS/LIMITATIONS*: The System must not be used with automated insulin dosing (AID) systems, including closed loop and insulin suspend systems. Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment. Do not take high doses of vitamin C (more than 500 mg per day), as this may falsely raise your Sensor readings. Failure to use the System according to the instructions for use may result in missing a severe low blood glucose or high blood glucose event and/or making a treatment decision that may result in injury. If glucose alarms and readings from the System do not match symptoms or expectations, use a fingerstick blood glucose value to make diabetes treatment decisions. Seek medical attention when appropriate and contact Abbott Toll Free (855-632-8658) or visit* www.freestylelibre.us for detailed indications for use and safety information. *For full indications for use and safety information, see more here. The shape of the circle sensor unit, FreeStyle, Libre, and related brand marks are owned by Abbott. Other trademarks are property of their respective owners.

No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.

The product images are for illustrative purposes only.

This website and the information contained herein is intended for use by residents of the United States.